Skip to main content
OpenTrials
Completed

NCT Number: NCT03572413

The Effect of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery on Innate Immune Homeostasis.

Substudy of the RECOVER trial (a randomised controlled trial comparing the effect of low pressure pneumoperitoneum with deep neuromuscular block versus normal pressure pneumoperitoneum with moderate neuromuscular block during laparoscopic colorectal surgery on early quality of recovery) investigating innate immune homeostasis after laparoscopic colorectal surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Canisius Wilhelmina Hospital

Nijmegen, Gelderland, 6532SZ, Netherlands

About this study

Rationale: increased intra-abdominal pressure can cause peritoneal mesothelial cell injury either directly or by compression of the capillary vessels, causing a variable degree of ischemia reperfusion injury. The immune system can identify damage to host cells by recognising Danger-Associated Molecular Patterns (DAMPs) that are released upon cell death in an uncontrolled fashion, such as during surgical trauma. DAMPs elicit an immune response similar to the response to invading pathogens and induce an anti-inflammatory immune response strongly related to postoperative recovery, infectious complications and mortality. Low pressure PNP is associated with lower levels of serum pro- and anti-inflammatory cytokines and better preservation of innate immune function.

Objective: to establish the relationship between the use of low pressure pneumoperitoneum with deep neuromuscular blockade and innate immune function after laparoscopic colorectal surgery.

Study design: a multi-center, blinded, randomized controlled clinical trial.

Study population: adult individuals scheduled for laparoscopic colorectal surgery with a primary colonic anastomosis.

Intervention: participants will be randomly assigned in a 1:1 fashion to either the experimental group (group A): low pressure PNP (8 mmHg) with deep NMB (PTC 1-2) or the control group (group B): normal pressure PNP (12 mmHg) with moderate NMB (TOF count 1-2).

Primary endpoint: mononuclear cell responsiveness ex-vivo as reflected by TNFα release upon LPS stimulation.

Secondary endpoints: mononuclear cell responsiveness ex-vivo as reflected by IL-6, IL-10 and IL-1beta release upon LPS stimulation. Peritoneal mesothelial hypoxia as reflected by peritoneal HIF1α mRNA expression, histological peritoneal mesothelial cell injury and plasma levels of DAMPs and cytokines.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Scheduled for laparoscopic colorectal surgery with a primary anastomosis
  • Obtained informed consent
  • Age over 18 years

Exclusion criteria

  • Insufficient control of the Dutch language to read the patient information and to fill out the questionnaires
  • Primary colostomy
  • Neo-adjuvant chemotherapy
  • Chronic use of analgesics or psychotropic drugs
  • Use of NSAIDs shorter than 5 days before surgery
  • Known or suspected allergy to rocuronium of sugammadex
  • Neuromuscular disease
  • Indication for rapid sequence induction
  • Severe liver- or renal disease (creatinine clearance <30ml/min)
  • BMI >35 kg/m²
  • Deficiency of vitamin K dependent clotting factors or coagulopathy

Treatment and study plan

Low Pressure Pneumoperitoneum

Procedure

Lowering intra-abdominal pressure during laparoscopic surgery

Other names: Low intra-abdominal pressure

Rocuronium bromide

Drug

Deep (PTC 1-2) versus moderate (TOF count 1-2) neuromuscular block

Other names: Deep muscle relaxation

Primary outcomes

  1. Mononuclear cell responsiveness ex vivo

    Time frame: Before surgery, 24 and 72 hours after surgery

    TNFalpha release upon LPS stimulation

Secondary outcomes

  1. Mononuclear cell responsiveness ex-vivo

    Time frame: Before surgery, 24 and 72 hours after surgery

    IL-6, IL-10 and IL-1beta release upon LPS stimulation

  2. Serum DAMPs and cytokines

    Time frame: Before surgery, at the end of surgery and 24 hours after surgery

    Danger associated molecular patterns, TNFalpha, IL-6 and IL-10

  3. HLA-DR mRNA expression

    Time frame: Before surgery, 24 and 72 hours after surgery

    MHC-II antigen presenting immune receptor

  4. Peritoneal histology and HIF1alpha expression

    Time frame: At the start and end of surgery

    Histology and HIF1alpha mRNA expression of a peritoneal biopsy

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

The Effectiveness of Low Pressure Pneumoperitoneum During Laparoscopic Colorectal Surgery in Preserving Innate Immune Homeostasis by Reducing Peritoneal Mesothelial Cell Injury.

Acronym: RECOVER-PLUS

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Jun 28, 2018
Registry last updated
Nov 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.